About Novavax (NASDAQ:NVAX)
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:NVAX
- CUSIP: 67000210
- Web: www.novavax.com
Capitalization:- Market Cap: $304.39 million
- Outstanding Shares: 294,183,000
Average Prices:- 50 Day Moving Avg: $1.14
- 200 Day Moving Avg: $1.06
- 52 Week Range: $0.73 - $1.78
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.91
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $21.04 million
- Price / Sales: 14.68
- Book Value: ($0.20) per share
- Price / Book: -5.25
Profitability:- EBITDA: ($186,640,000.00)
- Net Margins: -1,006.00%
- Return on Equity: -787.38%
- Return on Assets: -53.89%
Debt:- Debt-to-Equity Ratio: -5.37%
- Current Ratio: 3.54%
- Quick Ratio: 3.54%
Misc:- Average Volume: 5.80 million shs.
- Beta: 1.97
- Short Ratio: 5.54
Frequently Asked Questions for Novavax (NASDAQ:NVAX)
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.16). The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. Novavax's quarterly revenue was up 168.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.29) EPS. View Novavax's Earnings History.
Where is Novavax's stock going? Where will Novavax's stock price be in 2017?
8 brokerages have issued 12-month target prices for Novavax's stock. Their forecasts range from $1.50 to $12.00. On average, they expect Novavax's stock price to reach $3.35 in the next year. View Analyst Ratings for Novavax.
What are analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (8/19/2017)
- 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
- 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)
Are investors shorting Novavax?
Novavax saw a decline in short interest in September. As of September 29th, there was short interest totalling 47,385,568 shares, a decline of 12.6% from the September 15th total of 54,225,598 shares. Based on an average daily volume of 4,572,248 shares, the days-to-cover ratio is presently 10.4 days. Approximately 16.3% of the shares of the company are short sold.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Celyad SA (CYAD), Inovio Pharmaceuticals (INO), Mesoblast Limited (MESO), PDL BioPharma (PDLI), TG Therapeutics (TGTX), ImmunoGen (IMGN), Adamas Pharmaceuticals (ADMS), Agenus (AGEN), Kala Pharmaceuticals (KALA), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA), Codexis (CDXS), Corvus Pharmaceuticals (CRVS), Puretech Health PLC (PRTC) and NewLink Genetics Corporation (NLNK).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- James Francis Young Ph.D., Independent Chairman of the Board
- Stanley C. Erck, President, Chief Executive Officer, Director
- Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
- Gregory M. Glenn M.D., President, Research and Development
- John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
- John J. Trizzino, Senior Vice President - Commercial Operations
- James F. Cummings, Vice President - Clinical Development and Translational Medicine
- Rajiv I. Modi Ph.D., Director
- Gail Koziara Boudreaux, Independent Director
- Richard H. Douglas Ph.D., Independent Director
How do I buy Novavax stock?
Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of Novavax stock can currently be purchased for approximately $1.05.
MarketBeat Community Rating for Novavax (NASDAQ NVAX)MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Novavax (NASDAQ:NVAX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $3.35 (219.05% upside) |
Consensus Price Target History for Novavax (NASDAQ:NVAX)
Analysts' Ratings History for Novavax (NASDAQ:NVAX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/6/2017 | Seaport Global Securities | Reiterated Rating | Neutral | | N/A |  |
| 8/9/2017 | Ladenburg Thalmann Financial Services | Upgrade | Neutral -> Buy | $1.60 | High | |
| 7/27/2017 | Chardan Capital | Reiterated Rating | Neutral | $1.50 | Low | |
| 7/26/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $1.50 | Low | |
| 7/21/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $2.00 | Low | |
| 1/18/2017 | FBR & Co | Reiterated Rating | Outperform | $12.00 | N/A | |
| 11/11/2016 | Wedbush | Reiterated Rating | Neutral | $2.00 -> $1.50 | N/A | |
| 11/10/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 9/16/2016 | S&P Equity Research | Lower Price Target | | $1.44 -> $1.17 | N/A | |
| 9/16/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $12.00 -> $1.50 | N/A | |
| 8/29/2016 | Guggenheim | Reiterated Rating | Buy | $25.00 | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Novavax (NASDAQ:NVAX)Earnings History by Quarter for Novavax (NASDAQ NVAX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | ($0.16) | ($0.16) | $6.15 million | $6.70 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.18) | ($0.16) | $6.17 million | $5.68 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.23) | ($0.21) | $5.45 million | $5.40 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.26) | ($0.24) | $4.02 million | $3.20 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.25) | ($0.29) | $8.03 million | $2.50 million | View | Listen | |
| 5/4/2016 | Q1 | ($0.27) | ($0.29) | $10.39 million | $4.20 million | View | Listen | |
| 2/29/2016 | Q415 | ($0.14) | ($0.29) | $8.07 million | $5.90 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.09) | ($0.12) | $10.59 million | $6.50 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.09) | ($0.08) | $9.90 million | $14.00 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.11) | ($0.10) | $9.70 million | $9.88 million | View | N/A | |
| 2/26/2015 | Q4 14 | ($0.08) | ($0.13) | $9.60 million | $6.70 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.07) | ($0.08) | $9.20 million | $8.20 million | View | N/A | |
| 8/6/2014 | Q214 | ($0.07) | ($0.08) | $8.74 million | $8.26 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.07) | ($0.07) | $3.80 million | $7.50 million | View | N/A | |
| 3/10/2014 | Q413 | ($0.08) | ($0.07) | $6.22 million | $8.70 million | View | N/A | |
| 11/7/2013 | Q313 | ($0.06) | ($0.09) | $4.56 million | $4.80 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.06) | ($0.08) | $4.45 million | $3.50 million | View | N/A | |
| 5/7/2013 | Q1 2013 | ($0.06) | ($0.07) | $5.54 million | $3.80 million | View | N/A | |
| 3/1/2013 | Q4 2012 | ($0.04) | ($0.06) | $5.85 million | $4.57 million | View | N/A | |
| 11/2/2012 | Q312 | ($0.05) | ($0.05) | $7.59 million | $5.80 million | View | N/A | |
| 8/3/2012 | | ($0.07) | ($0.05) | | | View | N/A | |
| 5/4/2012 | | ($0.04) | ($0.06) | | | View | N/A | |
| 3/9/2012 | | ($0.04) | ($0.03) | | | View | N/A | |
| 11/4/2011 | | ($0.06) | ($0.03) | | | View | N/A | |
| 8/5/2011 | | ($0.08) | ($0.04) | | | View | N/A | |
| 5/9/2011 | | ($0.07) | ($0.07) | | | View | N/A | |
| 3/28/2011 | | ($0.09) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Novavax (NASDAQ:NVAX)2017 EPS Consensus Estimate: ($0.66)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.19) | ($0.17) | ($0.18) |
| Q2 2017 | 2 | ($0.16) | ($0.16) | ($0.16) |
| Q3 2017 | 2 | ($0.17) | ($0.16) | ($0.17) |
| Q4 2017 | 2 | ($0.16) | ($0.14) | ($0.15) |
(Data provided by Zacks Investment Research)
Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 45.17%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2017 | James F. Young | Director | Sell | 175,000 | $1.06 | $185,500.00 | |
| 7/31/2017 | Barclay A. Phillips | CFO | Buy | 2,057 | $0.89 | $1,830.73 | |
| 5/12/2017 | Michael A Mcmanus Jr | Director | Buy | 20,000 | $0.97 | $19,400.00 | |
| 5/11/2017 | Barclay A Phillips | CFO | Buy | 25,000 | $0.84 | $21,000.00 | |
| 5/11/2017 | Michael A Mcmanus Jr | Director | Buy | 10,000 | $0.84 | $8,400.00 | |
| 5/11/2017 | Stanley C Erck | Insider | Buy | 50,000 | $0.84 | $42,000.00 | |
| 1/31/2017 | Barclay A. Phillips | CFO | Buy | 1,633 | $1.12 | $1,828.96 | |
| 1/31/2017 | John A. Herrmann III | SVP | Buy | 4,960 | $1.12 | $5,555.20 | |
| 12/7/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.45 | $1,450.00 | |
| 9/22/2016 | John Trizzino | SVP | Buy | 46,000 | $2.17 | $99,820.00 | |
| 9/21/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.65 | $1,650.00 | |
| 9/21/2016 | Michael A Mcmanus Jr | Director | Buy | 30,000 | $1.61 | $48,300.00 | |
| 9/20/2016 | Gail Boudreaux | Director | Buy | 100,000 | $1.45 | $145,000.00 | |
| 7/31/2016 | Barclay A. Phillips | CFO | Buy | 422 | $4.29 | $1,810.38 | |
| 6/6/2016 | Gary C Evans | Director | Sell | 18,998 | $6.50 | $123,487.00 | |
| 5/24/2016 | Gary C Evans | Director | Sell | 50,000 | $5.41 | $270,500.00 | |
| 3/31/2016 | Stanley C Erck | CEO | Sell | 424,778 | $5.19 | $2,204,597.82 | |
| 1/31/2016 | Barclay A. Phillips | CFO | Buy | 405 | $4.38 | $1,773.90 | |
| 1/31/2016 | Gregory M. Glenn | SVP | Buy | 2,369 | $4.38 | $10,376.22 | |
| 1/31/2016 | Stanley C. Erck | CEO | Buy | 2,072 | $4.38 | $9,075.36 | |
| 12/16/2015 | John A Herrmann III | SVP | Sell | 27,945 | $8.64 | $241,444.80 | |
| 8/24/2015 | Gary C Evans | Director | Sell | 20,000 | $11.24 | $224,800.00 | |
| 8/20/2015 | Barclay A. Phillips | CFO | Sell | 28,656 | $13.06 | $374,247.36 | |
| 8/18/2015 | Gregory M. Glenn | SVP | Sell | 15,000 | $13.52 | $202,800.00 | |
| 8/13/2015 | Gary C Evans | Director | Sell | 6,002 | $13.56 | $81,387.12 | |
| 6/18/2015 | James F Young | Director | Sell | 50,000 | $9.47 | $473,500.00 | |
| 6/17/2015 | Rajiv I Modi | Director | Sell | 433,053 | $9.01 | $3,901,807.53 | |
| 6/11/2015 | Rajiv I Modi | Director | Sell | 11,185 | $9.00 | $100,665.00 | |
| 6/10/2015 | Rajiv I Modi | Director | Sell | 551,081 | $8.97 | $4,943,196.57 | |
| 6/9/2015 | Rajiv I Modi | Director | Sell | 47,531 | $8.93 | $424,451.83 | |
| 6/8/2015 | Rajiv I Modi | Director | Sell | 206,175 | $8.93 | $1,841,142.75 | |
| 6/4/2015 | Rajiv I Modi | Director | Sell | 504,681 | $8.92 | $4,501,754.52 | |
| 6/1/2015 | Rajiv I Modi | Director | Sell | 3,500,000 | $8.74 | $30,590,000.00 | |
| 1/31/2015 | Barclay A Phillips | CFO | Buy | 8,388 | $2.28 | $19,124.64 | |
| 1/31/2015 | John Trizzino | SVP | Buy | 6,611 | $3.63 | $23,997.93 | |
| 1/31/2015 | Stanley C Erck | CEO | Buy | 6,122 | $2.28 | $13,958.16 | |
| 12/16/2014 | Gary C Evans | Director | Sell | 46,701 | $5.72 | $267,129.72 | |
| 12/12/2014 | Gary C Evans | Director | Sell | 30,000 | $5.77 | $173,100.00 | |
| 11/20/2014 | Rajiv I Modi | Director | Sell | 518,889 | $5.02 | $2,604,822.78 | |
| 11/18/2014 | Rajiv I Modi | Director | Sell | 1,481,111 | $5.00 | $7,405,555.00 | |
| 10/3/2014 | Barclay A Phillips | CFO | Buy | 5,000 | $4.11 | $20,550.00 | |
| 10/3/2014 | Timothy Jon Hahn | SVP | Buy | 2,500 | $4.05 | $10,125.00 | |
| 9/26/2014 | Gregory M Glenn | SVP | Sell | 16,809 | $4.16 | $69,925.44 | |
| 9/25/2014 | Timothy Jon Hahn | SVP | Buy | 9,000 | $4.17 | $37,530.00 | |
| 7/31/2014 | Barclay A Phillips | CFO | Buy | 8,788 | $2.28 | $20,036.64 | |
| 7/31/2014 | Russell P Wilson | SVP | Buy | 4,989 | $2.28 | $11,374.92 | |
| 7/31/2014 | Stanley C Erck | CEO | Buy | 6,788 | $2.28 | $15,476.64 | |
| 6/17/2014 | John Trizzino | SVP | Buy | 5,500 | $4.51 | $24,805.00 | |
| 6/16/2014 | John Trizzino | SVP | Buy | 16,500 | $4.51 | $74,415.00 | |
| 3/25/2014 | Barclay Phillips | CFO | Buy | 5,000 | $4.25 | $21,250.00 | |
| 3/25/2014 | Richard Douglas | Director | Buy | 50,000 | $4.33 | $216,500.00 | |
| 3/25/2014 | Stanley Erck | CEO | Buy | 10,000 | $4.27 | $42,700.00 | |
| 3/21/2014 | Pharmaceuticals Ltd Cadila | major shareholder | Sell | 3,000,000 | $4.95 | $14,850,000.00 | |
| 1/31/2014 | Barclay Phillips | CFO | Buy | 9,868 | $2.29 | $22,597.72 | |
| 1/31/2014 | Stanley Erck | CEO | Buy | 11,868 | $2.29 | $27,177.72 | |
| 1/31/2014 | Timothy Jon Hahn | SVP | Buy | 9,416 | $2.29 | $21,562.64 | |
| 6/12/2013 | Richard Douglas | Director | Buy | 50,000 | $1.90 | $95,000.00 | |
| 6/10/2013 | Timothy Jon Hahn | SVP | Buy | 21,000 | $1.88 | $39,480.00 | |
| 6/7/2013 | Gregory M Glenn | Insider | Buy | 2,000 | $1.92 | $3,840.00 | |
| 6/6/2013 | James F Young | Director | Buy | 100,000 | $1.91 | $191,000.00 | |
| 3/11/2013 | James F Young | Director | Buy | 100,000 | $2.03 | $203,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
| Source: |
|
| Date | Headline |
|---|
 | Comparing Novavax (NVAX) and Seattle Genetics (SGEN)
www.americanbankingnews.com - October 20 at 2:10 PM |
 | Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017
finance.yahoo.com - October 19 at 7:00 AM |
| Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017
finance.yahoo.com - October 19 at 7:00 AM |
 | Novavax: Down A CFO But Not Out - Seeking Alpha
seekingalpha.com - October 18 at 7:50 AM |
| Featured Company News - Novavax's CFO Resigns
finance.yahoo.com - October 17 at 3:21 AM |
| Novavax CFO Phillips resigns to pursue other opportunity in the industry
finance.yahoo.com - October 14 at 6:18 AM |
| Novavax announces a major leadership change
finance.yahoo.com - October 14 at 6:18 AM |
| Novavax Announces Leadership Change
finance.yahoo.com - October 13 at 7:34 AM |
| Novavax, Inc. (NVAX) Short Interest Update
www.americanbankingnews.com - October 13 at 1:58 AM |
| Novavax, Inc. (NVAX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 6:36 PM |
| Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax
finance.yahoo.com - October 9 at 3:57 PM |
| Equities Analysts Set Expectations for Novavax, Inc.'s FY2017 Earnings (NVAX)
www.americanbankingnews.com - October 9 at 3:16 AM |
| Novavax's (NVAX) Neutral Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM |
| Novavax: Beware Of The Siren Song - Seeking Alpha
seekingalpha.com - October 5 at 12:48 PM |
| How Should You Think About Novavax Inc’s (NVAX) Risks?
finance.yahoo.com - September 30 at 5:40 PM |
| Contrasting Novavax (NVAX) & Its Peers
www.americanbankingnews.com - September 29 at 6:24 PM |
 | Why Novavax, Inc. Could Be a Gold Mine for Growth Investors - Motley Fool
www.fool.com - September 24 at 6:26 AM |
| Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
www.fool.com - September 23 at 10:50 AM |
| Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?
www.fool.com - September 21 at 3:47 PM |
| Novavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults
finance.yahoo.com - September 20 at 7:07 AM |
| Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults
finance.yahoo.com - September 20 at 7:07 AM |
| Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 7:07 AM |
| Novavax, Inc. (NVAX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 6:48 PM |
| Novavax: Catalysts Building Toward A Crescendo - Novavax, Inc ... - Seeking Alpha
seekingalpha.com - September 14 at 8:31 AM |
| ETFs with exposure to Novavax, Inc. : September 6, 2017
finance.yahoo.com - September 6 at 7:01 AM |
| Financial Comparison: Inovio Pharmaceuticals (INO) versus Novavax (NVAX)
www.americanbankingnews.com - September 2 at 4:10 PM |
| Insider Selling: Novavax, Inc. (NVAX) Director Sells 175,000 Shares of Stock
www.americanbankingnews.com - September 1 at 8:04 PM |
| Head to Head Contrast: Novavax (NVAX) vs. ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - August 27 at 6:20 AM |
| ETFs with exposure to Novavax, Inc. : August 25, 2017
finance.yahoo.com - August 26 at 7:51 AM |
| Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax, Inc.
www.fool.com - August 25 at 12:47 PM |
 | Novavax (NVAX) Reports Publication of Pre-Clinical Influenza Nanoparticle ...
www.streetinsider.com - August 24 at 10:18 AM |
 | Novavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine
www.nasdaq.com - August 24 at 10:18 AM |
| Novavax (NVAX) Reports Publication of Pre-Clinical Influenza Nanoparticle Study for Nanoparticle Influenza Vaccine ... - StreetInsider.com
www.streetinsider.com - August 23 at 9:23 AM |
| Novavax: The Case For Going Long - Seeking Alpha
seekingalpha.com - August 23 at 9:23 AM |
| Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine
finance.yahoo.com - August 23 at 9:23 AM |
| Novavax, Inc. (NVAX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 22 at 6:50 PM |
| 3 Top Biotech Stocks Under $10
www.fool.com - August 19 at 1:20 PM |
| Novavax, Inc. :NVAX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 17 at 6:22 AM |
 | Why analysts think Novavax's flu vaccine could be a big deal
www.bizjournals.com - August 15 at 4:33 PM |
| The Hidden Gem in Novavax's Pipeline You'll Want to Watch
finance.yahoo.com - August 15 at 4:33 PM |
| The Hidden Gem in Novavax's Pipeline You'll Want to Watch
www.fool.com - August 15 at 3:28 PM |
 | Can Novavax Stage A Comeback In Q4? One Analyst Thinks So - Benzinga
www.benzinga.com - August 12 at 6:25 AM |
| Can Novavax Stage A Comeback In Q4? One Analyst Thinks So
finance.yahoo.com - August 12 at 6:25 AM |
| Novavax, Inc. (NASDAQ:NVAX) Announces Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - August 10 at 4:04 PM |
 | EARNINGS SUMMARY: Details of Novavax Inc. Q2 Earnings Report
www.rttnews.com - August 10 at 6:22 AM |
| Edited Transcript of NVAX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:22 AM |
| Novavax, Inc. (NASDAQ:NVAX) Upgraded to Buy at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - August 9 at 7:40 AM |
| Novavax Reaching Critical Mass? - Seeking Alpha
seekingalpha.com - August 9 at 5:35 AM |
| Investor Network: Novavax, Inc to Host Earnings Call
finance.yahoo.com - August 9 at 5:35 AM |
| Novavax Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:35 AM |
Novavax (NVAX) Chart for Friday, October, 20, 2017
